GSK and Sanofi join forces to work on coronavirus vaccine(2)

On Tuesday, Walmsley said GSK would not profit from the vaccine during the pandemic and that any revenue would be reinvested in scaling up manufacturing and into research on pandemic preparedness.

总部位于法国的赛诺菲今年2月宣布，它将加入生产疫苗的行列，并已获得美国卫生部门的支持。

来源：卫报、参考消息网

synthesize[snθsaz]：vt.合成;综合

Sanofi, which is headquartered in France, announced in February that it was entering the race to make a vaccine and had secured support from the US health department.

[来源:China Daily] 2020-04-18 11:45:57

adjuvant['dv()nt]：n.佐药;辅助物

编辑：yaning(China Daily)

When the coronavirus invades the body, immune cells fight back by producing antibodies. These antibodies bind to specific structures on the foreign invader, called the antigen. In the case of Covid-19 the antigen is a spike-like protein on its exterior.

The pairing is significant because, if successful, the two companies have the capacity to manufacture the hundreds of millions of doses that are likely to be required worldwide.

Two companies joining forces, rather than competing, in a vaccine effort is extremely unusual, but the urgent need for a Covid-19 vaccine and the potential scale of the market is also not a typical situation.

GlaxoSmithKline and Sanofi, which combined have the largest vaccine manufacturing capability in the world, are working together on a hi-tech vaccine they say could be in human trials within months.

世界上最大的两家疫苗公司展开“前所未有”的合作，联手研发新冠肺炎疫苗。

当新冠病毒入侵人体时，免疫细胞通过产生抗体进行反击。这些抗体会与外来入侵者身上的特定结构结合在一起，这些特定结构被称为抗原。就新冠病毒而言，抗原是其表面的一种刺突状蛋白。

GSK is contributing an add-on, known as an adjuvant, that can be mixed in with a vaccine to trigger a stronger immune reaction. The same technology was used in the H1N1 flu pandemic.

两家公司合作研发的这种疫苗将基于赛诺菲用于生产流感疫苗的现有脱氧核糖核酸(DNA)技术。

两家公司在疫苗研发领域展开合作而不是竞争，这是极其罕见的。不过，对于新冠疫苗的迫切需求和市场的潜在规模也并不常见。

GSK and Sanofi join forces to work on coronavirus vaccine

新湖南新闻客户端  >  垂直  >  双语EN  >  international news

Sanofi has synthesized a stretch of DNA that encodes the genetic sequence of that protein. When this DNA is inserted into a harmless bacteria in the lab, it churns out little copies of the antigen – but not of the active coronavirus itself– which it hopes will trigger an antibody response, without causing illness.